These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 29991523)
21. Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means. Ambrosy AP; Velazquez EJ Am Heart J; 2018 May; 199():176-177. PubMed ID: 29754658 [No Abstract] [Full Text] [Related]
27. Neprilysin inhibition for heart failure. Timmis A N Engl J Med; 2014 Dec; 371(24):2336. PubMed ID: 25494278 [No Abstract] [Full Text] [Related]
28. ACP Journal Club: in HF, angiotensin-neprilysin inhibition reduced mortality and HF hospitalization compared with enalapril. Schmitt BP Ann Intern Med; 2015 Feb; 162(4):JC2. PubMed ID: 25686189 [No Abstract] [Full Text] [Related]
29. [Heart failure and LCZ696]. Sabourin G Perspect Infirm; 2015; 12(1):61. PubMed ID: 25651686 [No Abstract] [Full Text] [Related]
30. Neprilysin Inhibitors: Emerging Therapy for Heart Failure. Owens AT; Brozena S; Jessup M Annu Rev Med; 2017 Jan; 68():41-49. PubMed ID: 27686019 [TBL] [Abstract][Full Text] [Related]
31. Angiotensin-Neprilysin Inhibition as a Paradigm for All? Vaduganathan M; Desai AS Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488 [TBL] [Abstract][Full Text] [Related]
34. Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. Ramos IC; Versteegh MM; de Boer RA; Koenders JMA; Linssen GCM; Meeder JG; Rutten-van Mölken MPMH Value Health; 2017 Dec; 20(10):1260-1269. PubMed ID: 29241885 [TBL] [Abstract][Full Text] [Related]
35. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Desai AS; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Chen F; Gong J; Rizkala AR; Brahimi A; Claggett B; Finn PV; Hartley LH; Liu J; Lefkowitz M; Shi V; Zile MR; Solomon SD Eur Heart J; 2015 Aug; 36(30):1990-7. PubMed ID: 26022006 [TBL] [Abstract][Full Text] [Related]
36. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ; JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471 [TBL] [Abstract][Full Text] [Related]
37. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. Balmforth C; Simpson J; Shen L; Jhund PS; Lefkowitz M; Rizkala AR; Rouleau JL; Shi V; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV JACC Heart Fail; 2019 Jun; 7(6):457-465. PubMed ID: 31078482 [TBL] [Abstract][Full Text] [Related]
38. Role of Neprilysin Inhibitors in Heart Failure. Salazar Adum JP; Arora R Am J Ther; 2017; 24(6):e737-e743. PubMed ID: 26580582 [TBL] [Abstract][Full Text] [Related]
39. The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction. Kjeldsen SE; Narkiewicz K; Burnier M; Oparil S Blood Press; 2019 Aug; 28(4):215-216. PubMed ID: 31184508 [No Abstract] [Full Text] [Related]
40. Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction. Briasoulis A; Kuno T; Ueyama H Am J Cardiol; 2021 Aug; 153():150-152. PubMed ID: 34210504 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]